PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Summary

So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival

Timeline

Start

2021-12-23

Primary completion

2028-11-30

Completion

2028-11-30

Drugs

Indications